Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer

BACKGROUND: The development of immune checkpoint inhibitors (ICIs) is a revolutionary milestone in the field of immune-oncology. However, the low response rate is the major problem of ICI treatment. The recent studies showed that response rate to single-agent programmed cell death protein 1 (PD-1)/p...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Jiehan, Jin, Zheng, Zhang, Yiqun, Peng, Ling, Zhang, Yue, Zhu, Zhiruo, Wang, Yaohui, Tong, De, Yang, Yining, Wang, Jianfei, Yang, Yadong, Xiao, Kui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076602/
https://www.ncbi.nlm.nih.gov/pubmed/33927719
http://dx.doi.org/10.3389/fimmu.2021.646874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076602/
https://www.ncbi.nlm.nih.gov/pubmed/33927719
http://dx.doi.org/10.3389/fimmu.2021.646874

Ejemplares similares